Protein C and acute inflammation: A clinical and biological perspective

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 305, Issue 7, 2013, Pages

  Christiaans, Sarah C ^a   Wagener, Brant M ^a   Esmon, Charles T ^b   Pittet, Jean Francois ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

ARDS; Histone; Protein C; Sepsis; Trauma

Indexed keywords

ACTIVATED PROTEIN C; ENZYME PRECURSOR; PROTEIN C;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CELL PROTECTION; DISEASE SEVERITY; FULMINATING PURPURA; HUMAN; INFLAMMATION; INJURY; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVAL;

ARDS; HISTONE; PROTEIN C; SEPSIS; TRAUMA;

ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD COAGULATION; HUMANS; INFLAMMATION; PROTEIN C; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS;

EID: 84884933962     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00093.2013     Document Type: Article

References (110)

1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa in Early Stage Severe Sepsis Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332-1341, 2005.
2. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost 9: 1795-1803, 2011.
3. Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, Siami S, Chagnon JL, Constantin JM, Petitpas F, Souweine B, Amathieu R, Forceville X, Charpentier C, Tesniere A, Chastre J, Bohe J, Colin G, Cariou A, Renault A, Brun-Buisson C, Bellissant E; APROCCHSS Trial Investigators. Recombinant human activated protein C for adults with septic shock. Am J Respir Crit Care Med 187: 1091-1097, 2013.
4. Asakura H, Ontachi Y, Mizutani T, Kato M, Ito T, Saito M, Morishita E, Yamazaki M, Aoshima K, Takami A, Yoshida T, Suga Y, Miyamoto K, Nakao S. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 67: 170-175, 2001.
5. Baratto F, Michielan F, Meroni M, Dal Palu A, Boscolo A, Ori C. Protein C concentrate to restore physiological values in adult septic patients. Intensive Care Med 34: 1707-1712, 2008.
6. Barie PS, Hydo LJ, Shou J, Eachempati SR. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surg Infect (Larchmt) 12: 443-449, 2011.
7. Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 113: 7-17, 2004.
8. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051-2059, 2001.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709, 2001.
10. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33: 426-434, 2007.
11. Bir N, Lafargue M, Howard M, Goolaerts A, Roux J, Carles M, Cohen MJ, Iles KE, Fernandez JA, Griffin JH, Pittet JF. Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosainduced lung injury in mice. Am J Respir Cell Mol Biol 45: 632-641, 2011.
12. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 303: 1532-1535, 2004.
13. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 13: 680-685, 2007.
14. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 54: 1127-1130, 2003.
15. Chesebro BB, Rahn P, Carles M, Esmon CT, Xu J, Brohi K, Frith D, Pittet JF, Cohen MJ. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 32: 659-665, 2009.
16. Choi G, Hofstra JJ, Roelofs JJ, Florquin S, Bresser P, Levi M, van der Poll T, Schultz MJ. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 35: 1362-1368, 2007.
17. Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam 2011: 367284, 2011.
18. Cohen MJ, Call M, Nelson M, Calfee CS, Esmon CT, Brohi K, Pittet JF. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 255: 379-385, 2012.
19. Cole E, Davenport R, De'Ath H, Manson J, Brockamp T, Brohi K. Coagulation system changes associated with susceptibility to infection in trauma patients. J Trauma Acute Care Surg 74: 51-57; discussion 57-58, 2013.
20. Cornet AD, Hofstra JJ, Vlaar AP, Tuinman PR, Levi M, Girbes AR, Schultz MJ, Groeneveld AB, Beishuizen A. Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. J Thromb Haemost 11: 894-901, 2013.
21. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 407: 258-264, 2000.
22. Crivellari M, Della Valle P, Landoni G, Pappalardo F, Gerli C, Bignami E, Marino G, Zangrillo A, D'Angelo A. Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery. Intensive Care Med 35: 1959-1963, 2009.
23. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362: 779-789, 2010.
24. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, Hazelzet JA. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31: 1839-1847, 2003.
25. Decembrino L, D'Angelo A, Manzato F, Solinas A, Tumminelli F, De Silvestri A, De Lazzari S, Padovani E, Magarotto M, Chiandetti L, Saia SO, Stronati M. Protein C concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: a pilot study. Shock 34: 341-345, 2010.
26. Decruyenaere J, De Backer D, Spapen H, Laterre PF, Raemaekers J, Rogiers P, Trine H, Sartral M, Haentjens T, Wagner T. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study. Acta Clin Belg 64: 16-22, 2009.
27. Dhainaut JF, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, Charpentier J, Belger M, Cobas-Meyer M, Maier C, Mignini MA, Janes J. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med 35: 1187-1195, 2009.
28. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 33: 341-348, 2005.
29. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 14: R180, 2010.
30. Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, Young JK, Cooper LM. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs. Curr Med Res Opin 23: 235-244, 2007.
31. Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 109: 416-420, 2013.
32. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 5: 141-148, 1995.
33. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Perez XL, Sirvent JM; Edusepsis Study Group. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 180: 861-866, 2009.
34. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280: 17286-17293, 2005.
35. Fourrier F, Leclerc F, Aidan K, Sadik A, Jourdain M, Tournoys A, Noizet O. Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study. Intensive Care Med 29: 1081-1087, 2003.
36. Fuchs-Buder T, de Moerloose P, Ricou B, Reber G, Vifian C, Nicod L, Romand JA, Suter PM. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 153: 163-167, 1996.
37. Gale AJ, Heeb MJ, Griffin JH. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood 96: 585-593, 2000.
38. Ganopolsky JG, Castellino FJ. A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 165: 1433-1446, 2004.
39. Gentry CA, Gross KB, Sud B, Drevets DA. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 37: 19-25, 2009.
40. Goldstein B, Nadel S, Peters M, Barton R, Machado F, Levy H, Haney DJ, Utterback B, Williams MD, Giroir BP. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr Crit Care Med 7: 200-211, 2006.
41. Goolaerts A, Lafargue M, Song Y, Miyazawa B, Arjomandi M, Carles M, Roux J, Howard M, Parks DA, Iles KE, Pittet JF. PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice. Thorax 66: 788-796, 2011.
42. Griffin JH, Zlokovic BV, Mosnier LO. Protein C anticoagulant and cytoprotective pathways. Int J Hematol 95: 333-345, 2012.
43. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 161: 454-462, 2000.
44. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernandez JA, Griffin JH, Zlokovic BV. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41: 563-572, 2004.
45. Hardaway RM, Williams CH, Vasquez Y. Disseminated intravascular coagulation in sepsis. Semin Thromb Hemost 27: 577-583, 2001.
46. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 268: 2872-2877, 1993.
47. Higgins TL, Steingrub JS, Tereso GJ, Tidswell MA, McGee WT. Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes. J Intensive Care Med 20: 339-345, 2005.
48. Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, Zaat SA, Schultz MJ. Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care 13: R145, 2009.
49. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G, van der Poll T, Levi M, Schultz MJ. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 23: 105-111, 2010.
50. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 13: 1349-1358, 2007.
51. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Munoz A. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 37: 1185-1196, 2009.
52. Jourdain M, Carrette O, Tournoys A, Fourrier F, Mizon C, Mangalaboyi J, Goudemand J, Mizon J, Chopin C. Effects of inter-alphainhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am J Respir Crit Care Med 156: 1825-1833, 1997.
53. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 12: 678-686, 2012.
54. Kanji S, Perreault MM, Chant C, Williamson D, Burry L. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 33: 517-523, 2007.
55. Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. J Trauma 32: 2-11, 1992.
56. Kotanidou A, Loutrari H, Papadomichelakis E, Glynos C, Magkou C, Armaganidis A, Papapetropoulos A, Roussos C, Orfanos SE. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol 45: 134-140, 2006.
57. Kutcher ME, Xu J, Vilardi RF, Ho C, Esmon CT, Cohen MJ. Extracellular histone release in response to traumatic injury: implications for a compensatory role of activated protein C. J Trauma Acute Care Surg 73: 1389-1394, 2012.
58. Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, Carmeliet P. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 101: 4823-4827, 2003.
59. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704, 2004.
60. Lindenauer PK, Rothberg MB, Nathanson BH, Pekow PS, Steingrub JS. Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. Crit Care Med 38: 1101-1107, 2010.
61. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 178: 618-623, 2008.
62. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 55: 39-44, 2003.
63. Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 13: R103, 2009.
64. Maurice A, Seguin P, Aguillon D, Chanavaz C, Malledant Y. [Activated protein C treatment: experience about 23 patients in the operative period]. Ann Fr Anesth Reanim 24: 343-346, 2005.
65. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 30: 249-256, 2009.
66. Miller DL, Welty-Wolf K, Carraway MS, Ezban M, Ghio A, Suliman H, Piantadosi CA. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 26: 650-658, 2002.
67. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 109: 3161-3172, 2007.
68. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369: 836-843, 2007.
69. Neyrinck AP, Liu KD, Howard JP, Matthay MA. Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol 158: 1034-1047, 2009.
70. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/042 versus Ringer's acetate in severe sepsis. N Engl J Med 367: 124-134, 2012.
71. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 285: L20-L28, 2003.
72. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366: 2055-2064, 2012.
73. Rezaie AR. Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem 17: 2059-2069, 2010.
74. Ridley S, Lwin A, Wyncoll D, Lippett S, Watson D, Gunning K, Higgins D. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. Eur J Anaesthesiol 25: 211-216, 2008.
75. Rimmer E, Kumar A, Doucette S, Marshall J, Dial S, Gurka D, Dellinger RP, Sharma S, Penner C, Kramer A, Wood K, Ronald J, Kumar A, Turgeon AF, Houston DS, Zarychanski R; The Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Activated protein C and septic shock: a propensitymatched cohort study*. Crit Care Med 40: 2974-2981, 2012.
76. Rintala E, Kauppila M, Seppala OP, Voipio-Pulkki LM, Pettila V, Rasi V, Kotilainen P. Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28: 2373-2378, 2000.
77. Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 26: 965-968, 1998.
78. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 126: 646-652, 1995.
79. Robriquet L, Collet F, Tournoys A, Prangere T, Neviere R, Fourrier F, Guery BP. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 7: 41, 2006.
80. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 13: 657-670, 2002.
81. Rowan KM, Welch CA, North E, Harrison DA. Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care 12: R58, 2008.
82. Russo A, Soh UJ, Paing MM, Arora P, Trejo J. Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci USA 106: 6393-6397, 2009.
83. Sadaka F, O'Brien J, Migneron M, Stortz J, Vanston A, Taylor RW. Activated protein C in septic shock: a propensity-matched analysis. Crit Care 15: R89, 2011.
84. Schellongowski P, Bauer E, Holzinger U, Staudinger T, Frass M, Laczika K, Locker GJ, Quehenberger P, Rabitsch W, Schenk P, Knobl P. Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin). Vox Sang 90: 294-301, 2006.
85. Seeley EJ, Matthay MA, Wolters PJ. Inflection points in sepsis biology: from local defense to systemic organ injury. Am J Physiol Lung Cell Mol Physiol 303: L355-L363, 2012.
86. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 118: 1952-1961, 2011.
87. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, Sundin DP. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 10: R92, 2006.
88. Shorr AF, Janes JM, Artigas A, Tenhunen J, Wyncoll DL, Mercier E, Francois B, Vincent JL, Vangerow B, Heiselman D, Leishman AG, Zhu YE, Reinhart K; RESPOND investigators. Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Crit Care 14: R229, 2010.
89. Silvani P, Camporesi A, Licari E, Wolfler A. Use of protein C concentrate in pediatric patients with sepsis. Minerva Anestesiol 71: 373-378, 2005.
90. Slofstra SH, Groot AP, Maris NA, Reitsma PH, Cate HT, Spek CA. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 149: 740-746, 2006.
91. Smith OP, White B. Infectious purpura fulminans: caution needed in the use of protein c. Br J Haematol 106: 253-254, 1999.
92. Soh UJ, Trejo J. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through beta-arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci USA 108: E1372-E1380, 2011.
93. Song Y, Lynch SV, Flanagan J, Zhuo H, Tom W, Dotson RH, Baek MS, Rubio-Mills A, Singh G, Kipnis E, Glidden D, Brown R, Garcia O, Wiener-Kronish JP. Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology 106: 252-261, 2007.
94. Spiel AO, Firbas C, Mayr FB, Leitner JM, Schmidt B, Knobl P, Varadi K, Jilma B. The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia. Thromb Haemost 94: 1148-1155, 2005.
95. Spriet I, Meersseman W, Wilmer A, Meyfroidt G, Casteels M, Willems L. Evaluation of drotrecogin alpha use in a Belgian university hospital. Pharm World Sci 28: 290-295, 2006.
96. 2+ binding to both antigen and antibody. J Biol Chem 263: 826-832, 1988.
97. Steingrub JS, Cheatham ML, Woodward B, Wang HT, Effron MB; XEUS Investigators. A prospective, observational study of Xigris Use in the United States (XEUS). J Crit Care 25: 660. e9-16, 2010.
98. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918-925, 1987.
99. Veldman A, Fischer D, Wong FY, Kreuz W, Sasse M, Eberspacher B, Mansmann U, Schosser R. Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients. Crit Care 14: R156, 2010.
100. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33: 2266-2277, 2005.
101. Vincent JL, Laterre PF, Decruyenaere J, Spapen H, Raemaekers J, Damas F, Rogiers P, Sartral M, Haentjens T, Nelson D, Janes J. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units-an observational study. Acta Clin Belg 63: 25-30, 2008.
102. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 285: L514-L521, 2003.
103. Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Crit Care Med 36: 14-23, 2008.
104. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96: 3719-3724, 2000.
105. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S, CAPTIVATE Trial Group. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 183: 1561-1568, 2011.
106. Xu J, Esmon NL, Esmon CT. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 274: 6704-6710, 1999.
107. Xu J, Ji Y, Zhang X, Drake M, Esmon CT. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. J Thromb Haemost 7: 851-856, 2009.
108. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med 15: 1318-1321, 2009.
109. Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 32: S239-S246, 2004.
110. Yang XV, Banerjee Y, Fernandez JA, Deguchi H, Xu X, Mosnier LO, Urbanus RT, de Groot PG, White-Adams TC, McCarty OJ, Griffin JH. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci USA 106: 274-279, 2009.